Catalent Biologics Announces Agreement for SMA Drug Development

Published on: 

Pharmaceutical Executive

Catalent Biologics announced a strategic agreement to develop and manufacture Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).

Through this collaboration, AveXis, a Novartis company, will have dedicated manufacturing space at a new commercial manufacturing center established by Paragon Gene Therapy, a unit of Catalent Biologics. Paragon Gene Therapy will also provide process development for clinical supply of additional viral therapies in the AveXis pipeline.